InvestSMART

EZZ Life Science Holdings Limited (ASX:EZZ)

ALERT: Price-sensitive ASX Announcement for EZZ
Current share price for EZZ : $0.475 -0.23 (-32.62%)+
Announcement
Release
30 Apr 2026 4:54PM
Price at Release
$0.705
Full Release
download
Summary
EZZ Life Science Holdings Limited released its Quarterly Activity and Cashflow Report for the period ending 31 March 2026. The company recorded customer receipts of $8.85 million, reflecting a decline in consumer demand on key e-commerce platforms, and a net operating cash outflow of $3.2 million. Strategic initiatives included a four-year distribution agreement with Aumake Limited, and a cooperation framework with JD Health to enhance market execution in China. Product innovation continued with launches such as the MeTime Series and tailored children's products for China. EZZ expanded its pharmacy distribution network in Australia and maintained a cash balance of $9.96 million, remaining debt-free. The company aims to balance strategic investments with cost management to capture growth opportunities and deliver shareholder value.
Key Points
  • Customer receipts totalled $8.85 million in Q3 FY26.
  • Net operating cash outflow of $3.2 million.
  • Entered a four-year distribution agreement with Aumake Limited.
  • Cooperation framework established with JD Health.
  • Launched new products including the MeTime Series.
  • Expanded ANZ pharmacy distribution network.
  • Cash balance of $9.96 million, debt-free status maintained.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.